- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Interventions
- Vatalanib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 855 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 143
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 113 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 13,090
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endogenous Cushing's Syndrome
- Interventions
- Osilodrostat
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
- Conditions
- Participants Less Than 12 Months of Age With RSV Illness
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 12 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 24 more
- Conditions
- Brain Edema, Brain Tumor
- Interventions
- hCRF, placebo hCRF
- Drug
- Lead sponsor
- Celtic Pharma Development Services
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Fresno, California • Newport Beach, California + 22 more
- Conditions
- Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Lanraplenib, Gilteritinib
- Drug
- Lead sponsor
- Kronos Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • La Jolla, California • Loma Linda, California + 27 more
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
- Interventions
- CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more
- Conditions
- Hypertension
- Interventions
- Nebivolol, Valsartan and Hydrochlorothiazide
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more
- Conditions
- Major Depressive Disorder
- Interventions
- AXS-05, Bupropion
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 40
- States / cities
- Bellflower, California • Lafayette, California • Oceanside, California + 34 more
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
- Drug · Device
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more
- Conditions
- Obesity
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years to 15 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 26
- States / cities
- Escondido, California • Orlando, Florida • Tallahassee, Florida + 22 more
- Conditions
- Colorectal Cancer
- Interventions
- capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 119
- States / cities
- Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more
- Conditions
- Epilepsy
- Interventions
- Lacosamide
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more
- Conditions
- Human Immuno-deficiency Virus (HIV) Disease
- Interventions
- Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
- Conditions
- Malignant Melanoma
- Interventions
- Vemurafenib, Dacarbazine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, ALL
- Interventions
- rituximab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Kansas City, Missouri
- Conditions
- Chronic Kidney Diseases
- Interventions
- Ferric Citrate, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 14 more
- Conditions
- Cystitis, Interstitial, Ulcer
- Interventions
- LiRIS®, LiRIS Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Murrieta, California • Vacaville, California • Farmington, Connecticut + 14 more
- Conditions
- Von Willebrand Diseases
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Orange, California • Aurora, Colorado • Farmington, Connecticut + 19 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Bosutinib, imatinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 32
- States / cities
- Anaheim, California • Beverly Hills, California • Fountain Valley, California + 22 more
- Conditions
- Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS)
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Atrial Fibrillation, Inflammation, Atrial Flutter
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia